Exosome Therapeutics Developer Capricor (CAPR) Rating Increased to Buy at Zacks Investment Research

Capricor Therapeutics Inc (OTCMKTS:CAPR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, Analyst Ratings.Net reports. The brokerage currently has a $4.25 price objective on the stock. Zacks Investment Research‘s price objective indicates a potential upside of 15.18% from the stock’s current price.

According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “

Capricor Therapeutics (OTCMKTS:CAPR) traded down 0.54% during mid-day trading on Tuesday, hitting $3.69. 1,831 shares of the stock were exchanged. Capricor Therapeutics has a 52 week low of $3.05 and a 52 week high of $10.68. The company’s market capitalization is $59.98 million. The stock’s 50-day moving average is $4.11 and its 200 day moving average is $4.56.

Capricor Therapeutics (OTCMKTS:CAPR) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.18) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.08. On average, analysts anticipate that Capricor Therapeutics will post ($0.80) EPS for the current year.

Capricor Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company develops and commercializes regenerative medicine and large molecule products for the treatment of disease, with a primary focus on cardiovascular diseases. The Company has six drug candidates in stages of development, which include CAP-1002, CAP-1001, CSps, Exosomes, Cenderitide (OTCMKTS:CAPR) and CU-NP. The Company’s technology is based in cardiospheres (CSps), which are multi-cell clusters of cardiac derived cells. The Company’s product candidate, the cardiosphere-derived cells (CDC), is the single cell monolayer product of the CSps. Both CSps and CDCs are derived from a deceased human donor (allogeneic source) or from heart tissue taken directly from recipient patients themselves (autologous source).

Source – Dakota Financial News

Leave a Reply

Your email address will not be published. Required fields are marked *